Status:
COMPLETED
An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This observational study will evaluate the safety and efficacy of triple negative or HR+ patients with HER2-metastatic or locally advanced breast cancer treated with Avastin (bevacizumab) as first lin...
Eligibility Criteria
Inclusion
- Adult patients, \>/=18 years of age
- HER2-metastatic breast cancer or locally advanced breast cancer
- Patients with Avastin as first line therapy administered for at least 12 months
- Patients without disease progression after the beginning of Avastin treatment for at least 12 months
Exclusion
- Patients not willing to give informed consent
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
228 Patients enrolled
Trial Details
Trial ID
NCT01461044
Start Date
September 1 2011
End Date
November 1 2013
Last Update
January 26 2016
Active Locations (82)
Enter a location and click search to find clinical trials sorted by distance.
1
Aix-en-Provence, France, 13616
2
Aix-en-Provence, France, 13617
3
Ajaccio, France, 20176
4
Amiens, France, 80090